Live
- Modi: Ambedkar's vision neglected by Congress
- With holiday mood on a high, hotel room demand peaks in Hampi
- Vajpayee’s statue unveiled in Berhampur
- Bengal school job case: Special court hearing today to monitor progress of framing charges
- CM, Naveen pay tributes to Vajpayee
- Freedom fighter, veteran CPI leader R. Nallakannu turns 100 today
- Pravati inaugurates Dandadhar tourism site
- Applications invited for PM housing scheme
- SOT police seize 14 kg Ganja at Chouttuppal RTC bus stand
- Delhiites unhappy with AAP, will vote for BJP: Manoj
Zydus gets USFDA nod to market generic medication
Zydus Lifesciences on Wednesday said it has received approval from the US health regulator to market a generic product to treat a rare blood condition.
New Delhi: Zydus Lifesciences on Wednesday said it has received approval from the US health regulator to market a generic product to treat a rare blood condition.
The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Methylene Blue injection in strengths of 10mg/2ml and 50mg/5ml, the drug firm said in a statement. Zydus' product is the generic version of ProvayBlue injection.
The majority of current market usage is still on the ampoule presentation whereas Zydus is offering a generic version of Methylene Blue injection in vial presentation, the company stated. From a hospital perspective, a vial presentation is an affordable option with significant benefits and advantages, it added.
Methylene Blue injection is an oxidation-reduction agent indicated for the treatment of pediatric and adult patients with acquired methemoglobinemia. As per IQVIA MAT data, Methylene Blue injection (10mg/2ml and 50mg/5ml) had an annual sale of around USD 73.4 million in the US.
